AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca’s ROSY-D study, officially titled ‘Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab,’ aims to provide continued treatment for patients who have benefited from previous oncology studies involving Durvalumab. This study is significant as it seeks to extend the clinical benefits for patients who have shown positive outcomes in earlier trials.
The intervention being tested is Durvalumab, an experimental drug administered via a fixed dose of 1500 mg through IV infusion every four weeks. The purpose of this intervention is to maintain the therapeutic benefits observed in prior studies.
The study is designed as an open-label, non-randomized, multicenter, international trial with a sequential intervention model. There is no masking involved, and the primary purpose is treatment, allowing patients to continue receiving Durvalumab until discontinuation criteria are met.
The study commenced on April 19, 2022, with the last update submitted on August 13, 2025. These dates are crucial as they mark the study’s progression and provide a timeline for investors to track its development.
The continuation of the ROSY-D study could positively influence AstraZeneca’s stock performance by reinforcing investor confidence in the company’s oncology portfolio. As the study progresses, it may also impact the competitive landscape, especially if the results demonstrate significant clinical benefits.
The ROSY-D study is currently ongoing, with further details available on the ClinicalTrials portal.